SARS-CoV-2 seroprevalence and neutralizing activity in donor and patient blood from the San Francisco Bay Area

3

Dianna L. Ng^{*,1,2}, Gregory M. Goldgof^{*,1}, Brian R. Shy^{*,1}, Andrew G. Levine^{*,1}, Joanna 4 Balcerek^{*,1}, Sagar P. Bapat^{*,1}, John Prostko³, Mary Rodgers³, Kelly Coller³, Sandy Pearce³, 5 Sergej Franz⁵, Li Du⁵, Mars Stone^{1,5}, Satish K. Pillai⁵, Alicia Sotomayor-Gonzalez^{1,4}, Venice 6 Servellita^{1,4}, Claudia Sanchez San Martin^{1,4}, Andrea Granados^{1,4}, Dustin R. Glasner^{1,4}, Lucy M. 7 Han^{1,2}, Kent Truong^{1,2}, Naomi Akagi^{1,2}, David N. Nguyen⁶, Neil M. Neumann², Daniel Qazi², 8 Elaine Hsu¹, Wei Gu¹, Yale A. Santos^{1,4}, Brian Custer⁵, Valerie Green⁷, Phillip Williamson⁷, 9 Nancy K. Hills^{8,9}, Chuanyi M. Lu^{1,10}, Jeffrey D. Whitman¹, Susan Stramer¹¹, Candace Wang^{1,4}, 10 Kevin Reyes^{1,4}, Jill M.C. Hakim¹², Kirk Sujishi¹, Fariba Alazzeh¹, Lori Pham¹, Ching-Ying 11 Oon¹, Steve Miller^{1,4}, Theodore Kurtz¹, John Hackett, Jr.³, Graham Simmons^{1,5}, Michael P. 12 Busch^{1,5}, Charles Y. Chiu^{1,4,6,#} 13 14 15 ¹Department of Laboratory Medicine, University of California, San Francisco, San Francisco, 16 CA, USA 17 ²Department of Pathology, University of California, San Francisco, San Francisco, CA, USA 18 ³Applied Research and Technology, Abbott Diagnostics, Abbott Park, IL, USA 19 ⁴UCSF-Abbott Viral Diagnostics and Discovery Center, San Francisco, CA, USA 20 ⁵Vitalant Research Institute, San Francisco, CA, USA 21 ⁶Department of Medicine, Division of Infectious Diseases, University of California, San 22 23 Francisco, San Francisco, CA, USA 24 ⁷Creative Testing Solutions, Tempe, AZ, USA ⁸Department of Neurology, University of California, San Francisco, San Francisco, CA, USA 25 ⁹Department of Epidemiology and Biostatistics, University of California, San Francisco, San 26 27 Francisco, CA, USA ¹⁰ Lab Medicine Service, San Francisco VA Healthcare System 28 ¹¹American Red Cross, Gaithersburg, MD, USA 29 ¹²Department of Medicine at ZSFG, the Division of HIV, ID & Global Medicine 30 31

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

- 32 *These authors contributed equally to this work.
- 33 [#]Corresponding author.
- 34
- 35 Correspondence to:
- 36 Charles Y. Chiu, MD, PhD
- 37 Department of Laboratory Medicine,
- 38 185 Berry Street, Campus box 0134, San Francisco, CA 94107
- 39 E-mail: <u>charles.chiu@ucsf.edu</u>
- 40 Phone: (415) 514-8219
- 41
- 42

43 ABSTRACT

We report very low SARS-CoV-2 seroprevalence in two San Francisco Bay Area populations. Seropositivity was 0.26% in 387 hospitalized patients admitted for non-respiratory indications and 0.1% in 1,000 blood donors. We additionally describe the longitudinal dynamics of immunoglobulin-G, immunoglobulin-M, and *in vitro* neutralizing antibody titers in COVID-19 patients. Neutralizing antibodies rise in tandem with immunoglobulin levels following symptom onset, exhibiting median time to seroconversion within one day of each other, and there is >93% positive percent agreement between detection of immunoglobulin-G and neutralizing titers.

51

Coronavirus disease 2019 (COVID-19) is a novel respiratory illness caused by the severe acute 52 respiratory syndrome coronavirus 2 $(SARS-CoV-2)^{1}$. The symptoms of COVID-19 range from 53 54 asymptomatic infection to acute respiratory distress syndrome and death, and the COVID-19 pandemic has resulted in substantial burdens on healthcare systems worldwide^{2,3}. Given the 55 current state of diagnostic testing which largely relies on molecular techniques, the 56 57 seroprevalence of SARS-CoV-2-specific antibodies in different populations remains unclear. Accurate and large-scale serologic testing that includes detection of neutralizing antibodies is 58 59 essential in evaluating spread of infection in the community, informing public health 60 containment efforts, and identifying donors for convalescent plasma therapy trials.

- 61
- 62

63 Performance Characteristics of the Abbott Architect IgG and IgM SARS-CoV-2 Assays

64 We first assessed the performance of the Abbott Architect SARS-CoV-2 IgG (FDA 65 Emergency Use Authorization (EUA)) and IgM (prototype) assays from a cohort of five outpatients and 38 hospitalized patients at University of California, San Francisco (UCSF) 66 67 Medical Center and the San Francisco Veterans Affairs (SFVA) Health Care System. These assays are chemiluminescent microparticle immunoassays that target the nucleocapsid and spike 68 69 proteins, respectively. All patients received care at adult inpatient units or clinics and were RT-70 PCR positive for SARS-CoV-2 from nasopharyngeal and/or oropharyngeal swab testing (Figure 71 **1A, Table S1**). The percentage of patients seroconverting for IgG at weekly time intervals following reported symptom onset reached 94.4% at \geq 22 days (Figure 1B). Correspondingly, 72 73 IgG assay sensitivity from analysis of all 423 samples increased weekly to reach 96.9% at \geq 22 74 days, and was 99% when samples from seven immunocompromised patients (see below) were 75 excluded (Figure 1D, Table 1). The percentage of patients seroconverting for IgM was also 76 94.4% at \geq 22 days (Figure 1E) and IgM assay sensitivity from analysis of 346 samples was 77 97.9% (98.9% with immunocompromised patients excluded) (Figure 1G, Table 1).

78 Of the four patients who had not seroconverted for IgG by the end of 14 days (Figure 79 1B), two were kidney transplant recipients on tacrolimus and mycophenolate mofetil (MMF) 80 immunosuppressive therapy; one was >90 years old; and one was an asymptomatic patient 81 receiving acute psychiatric care who provided an unreliable history. Both renal transplant 82 recipients were observed to ultimately seroconvert for IgG and IgM. Notably, delayed 83 seroconversion for IgG and IgM was not universal in immunosuppressed patients: three 84 additional solid organ transplant (SOT) recipients on tacrolimus and MMF, as well as one patient with rheumatoid arthritis on methotrexate and infliximab, all seroconverted within two weeks. A 85 86 further SOT recipient was positive for IgG and IgM in the earliest available serum sample from day 17 post symptom onset (Figure 2D, E). We did not have samples beyond day 18 for the 87 88 remaining two patients. However, as seroconversion was observed as late as three weeks after 89 symptom onset (Figure 2D, E), it is possible that analysis of later samples would have 90 demonstrated detectable antibodies in their serum. The one patient who was still IgG negative in the 22+ day time frame (Figure 1B) (from a plasma sample collected on day 29) had only mild 91 92 symptoms and was positive by IgM and neutralizing antibody testing (described below). 93 Conversely, the one patient who was IgM negative in the 22+ day time frame was both IgG and

94 neutralizing antibody positive from a plasma sample collected on day 50 (Figure 1E), by whichh
95 time IgM antibody titers may have waned significantly.

96 To evaluate assay specificity, serum and plasma samples collected by Abbott 97 Laboratories from US blood donors prior to the COVID-19 pandemic (pre-COVID-19) were 98 tested for IgG (n=1,013) and IgM (n=1,492) seroreactivity. Two samples out of 1,013 were 99 positive by IgG testing, vielding a specificity of 99.8% (95% CI: 99.3-100%) (Figure 1C), 100 concordant with the 99.9% specificity reported in a study by the University of Washington^{4,5}. 101 Similarly, testing of 235 remnant plasma samples from 163 SARS-CoV-2 PCR-negative UCSF 102 patients collected from late March to early April 2020 resulted in detection of only one positive 103 sample, yielding a specificity of 99.6% (95% CI: 97.7-100%) (Figure 1H). The IgG positive 104 sample was from a patient admitted for syncope but who reported a cough of one-month 105 duration, suggesting a potential prior infection with SARS-CoV-2. Six samples out of 1,492 from 106 US blood donors were positive by IgM testing, yielding a specificity of 99.6% (95% CI: 99.2-107 99.9%) (Figure 1F). This was consistent with more limited testing of 39 SARS-CoV-2 PCR 108 negative UCSF patients, none of whom were positive for IgM antibody (Figure 1I). Thus, the 109 Architect SARS-CoV-2 IgG and IgM assays demonstrated high sensitivity (96.9%-97.9% at \geq 22 110 days in a primarily hospitalized patient cohort) and specificity (99.6-99.8% in pre-COVID blood 111 donors), with good correlation (rho = 0.65) between IgG anti-nucleocapsid protein and IgM anti-112 spike protein seropositivity (Figure 2A).

113

Seroprevalence of SARS-CoV-2 in blood donors and patients from the San Francisco Bay Area in March 2020

116 Next, to investigate SARS-CoV-2 seroprevalence in the San Francisco Bay Area, we 117 collected plasma and serum samples from two cohorts of individuals with low suspicion of 118 infection from COVID-19. One cohort consisted of 1,000 individuals who donated blood in 119 March 2020 at blood bank centers throughout the Bay Area (Figure 1A, Table S2). Routine 120 blood donor screening was performed to exclude those with self-reported symptoms of acute 121 illness and abnormal vital signs. We detected four IgG positive samples in this cohort, yielding a 122 seroreactivity rate of 0.40% (Figure 1H). This cohort was not tested for IgM antibody. We then 123 analyzed the four samples using two orthogonal tests, the VITROS anti-SARS-CoV-2 total 124 antibody assay (Ortho Clinical Diagnostics EUA) and a SARS-CoV-2 pseudovirus neutralization

assay (described below). Three of four samples were negative by both the VITROS and
neutralization assays, and thus were designated likely false positives by the Architect IgG assay.
Thus, the calculated seroprevalence after confirmatory orthogonal testing for Bay Area blood
donors in March 2020 was 0.1% (95% CI: 0.00% - 0.56%). The false positive rate in this
population of 0.3% is consistent with with the reported specificity of the Architect SARS-CoVIgG test of 99.6%⁴.

131 The other cohort for evaluating seroprevalence represented a cross-section of patients 132 who received care at adult inpatient units or clinics at the UCSF Medical Center for indications 133 other than COVID-19 respiratory disease (non-COVID-19, never tested for SARS-CoV-2 by 134 RT-PCR) from late March to early April 2020. Remnant samples from 532 blood draws taken 135 from these 387 patients were obtained from UCSF clinical laboratories. Of these 532 samples, 136 five were positive for IgG; strikingly, all five of these samples were from the same patient who 137 had respiratory failure and ground-glass opacities on chest imaging but was never tested for 138 SARS-2-CoV by RT-PCR (Figure 1H). IgG seroprevalence in this population was thus 0.26% 139 (95% CI: 0-0.76%). Although only 23 of the 532 remnant samples were able to be subsequently 140 tested for IgM antibodies, importantly, none were positive (Figure 1I).

- 141
- 142

143 Longitudinal dynamics of immunoglobulin and neutralizing antibody titers in SARS-CoV144 2 infected patient

We next analyzed the longitudinal dynamics of plasma IgG (286 samples) and IgM (249 samples) levels in our cohort of 43 patients who were positive for SARS-CoV-2 by PCR. As previously reported, IgG and IgM antibody levels were observed to rise approximately in tandem (**Figure 2D, E**)^{6–10}. We correlated median IgG, IgM, and neutralizing antibody (described below) levels at the weekly time intervals with severity of disease, and the differences were not statistically significant.

Lastly, we sought to correlate IgG and IgM seropositivity with SARS-CoV-2 *in vitro* neutralizing activity against a SARS-CoV-2 pseudovirus (a vesicular stomatitis virus (VSV) pseudotype expressing the SARS-CoV-2 spike protein). Plasma titers that achieved 80% neutralization of pseudovirus infectivity (NT80) were measured by luciferase assay (see Methods). We compared NT80 with IgG and IgM measurements in 54 available plasma samples

from 22 of the 43 SARS-CoV-2 PCR positive patients (**Figure 2B, C**). The positive percent agreement (PPA) between NT80 and IgG positivity was 93.8% and the negative percent agreement (NPA) was 75.0% (**Figure 2C**). Results from the NT80 and IgM comparison were similar, with a PPA of 84.8% and NPA of 78.6% (**Figure 2B**). Importantly, neutralizing titers appeared concomitantly in plasma with IgG and IgM positivity (**Figure 2D-G**), correlated well with IgG (*rho* = 0.79) and IgM (*rho* = 0.77) levels, and increased over time in parallel with the rise of anti-spike IgM and ant-nucleocapsid IgG antibodies (**Figure 2H-I**).

163

164 Conclusions

In this study, we provide evidence that seropositive results using the Architect SARS-165 166 CoV-2 anti-nucleocapsid protein IgG and anti-spike IgM assays are generally predictive of in 167 vitro neutralizing capacity. This correlation may have particular relevance for recovered COVID-168 19 patients and the identification of candidate donors to provide blood for convalescent plasma 169 therapy. However, *in vitro* neutralization activity may not confer protective immunity and the 170 efficacy of convalescent plasma therapy for treatment of COVID-19 disease remains to be 171 determined. Our results also show that the seroprevalence of IgG antibodies against SARS-CoV-172 2 in blood donors and non-COVID-19 patients seen at a tertiary care hospital in the San 173 Francisco Bay Area from March to April 2020 is very low at 0.10% (95% CI: 0.00% - 0.56%). 174 and 0.26% (0.00% - 0.76%), respectively. These seroprevalence rates in two distinct populations 175 in the San Francisco Bay Area are near the specificity limit of the Architect assay, and are far lower than the specificity limits for many lateral flow immunoassays¹¹. Our findings contrast 176 177 with those from other community-based studies that reported higher rates of seropositivity in California^{12,13}, and underscore the importance of using a highly accurate test for surveillance 178 179 studies in low-prevalence populations. They also indicate a very low likelihood of widespread 180 cryptic circulation of SARS-CoV-2 in the Bay Area prior to March 2020, consistent with the low 181 detection rate by direct viral testing of respiratory samples collected during that early time period¹⁴. 182

183

184 **METHODS**

185 Study design and Ethics

186 The study population consisted of patients with available remnant serum and plasma specimens 187 from the clinical laboratories at University of California, San Francisco (UCSF). Samples from 188 patients who were positive or negative by SARS-CoV-2 real-time polymerase chain reaction 189 (RT-PCR) testing of nasopharyngeal, oropharyngeal, and/or pooled nasopharyngeal-190 oropharyngeal swabs were collected in March - April 2020. Additional samples were collected 191 from randomly selected cohorts of outpatients and hospitalized patients at UCSF during the same 192 time period seen for indications other than COVID-19 respiratory disease (non-COVID). Serum 193 samples from blood donors in the San Francisco Bay Area were collected by Vitalant Research 194 Institute in March 2020. Clinical data for UCSF patients were extracted from electronic health records and entered in a HIPAA (Health Insurance Portability and Accountability Act)-secure 195 196 REDCap research database. Collected data included demographics, major comorbidities, patient-197 reported symptom onset date, clinical symptoms and indicators of COVID-19 severity such as 198 admission to the intensive care unit and requirement for mechanical ventilation. This study was 199 approved by the institutional review board (IRB) at UCSF (UCSF IRB #10-02598) as a no-200 subject contact study with waiver of consent.

201

202 Serologic testing

203 The Abbott Architect SARS-CoV-2 IgG assay (FDA Emergency Use Authorization (EUA)) and 204 SARS-CoV-2 IgM (prototype) testing was performed using either serum or plasma samples on the Architect instrument according to the manufacturer instructions⁴. These tests are 205 206 chemiluminescent microparticle immunoassay reactions that target the nucleocapsid protein (IgG 207 assay) or the spike protein (IgM assay) and measure relative light units that are then used to 208 calculate an index value. At a predefined index value threshold of 0.6 signal-to-cutoff (S/C) ratio 209 for IgM seropositivity and 1.4 S/C for IgG for seropositivity, these assays were found to have 210 specificities of 99.6% - 99.8%.

211

The VITROS anti-SARS-CoV-2 total antibody assay approved under FDA Emergency Use Authorization was performed using either serum or plasma samples at Vitalant Research Institute according to the manufacturer instructions¹⁵. The test is a chemiluminescent immunoassay that targets the spike protein and measures relative light units that are then used to calculate an index value. At a predefined index value threshold of 1.0 signal-to-cutoff (S/C) ratio for IgG

seropositivity, this assay was found to have a sensitivity of 100% (92.7% - 100%) and specificity of 100% (95% CI = 99.1% - 100.0%).

219

220 Production of pseudoviruses for the SARS-CoV-2 neutralization assay

221 $VSV\Delta G$ -luciferase-based viruses, in which the glycoprotein (G) gene has been replaced with 222 luciferase, were produced by transient transfection of viral glycoprotein expression plasmids (pCG SARS-CoV-2 Spike, provided courtesy of Stefan Pölhmann¹⁶, as well as pCAGGS VSV-G 223 224 or pCAGGS EboGP as controls) or no glycoprotein controls into HEK293T cells by TransIT-225 2020. Briefly, cells were seeded into 15-cm culture dishes and allowed to attach for 24 hours before transfection with 30 µg expression plasmid per plate. The transfection medium was 226 227 changed at approximately 16 hours post-transfection. The expression-enhancing reagent valproic 228 acid (VPA) was added to a final concentration of 3.75 mM, and the cells were incubated for three to four hours. The medium was changed again, and the cells were inoculated with VSVAG-229 230 luc virus at a multiplicity of infection (MOI) of 0.3 for four hours before the medium was 231 changed again. At about 24 hours post-infection, the supernatants were collected and cleared of 232 debris by filtration through a 0.45-µm syringe filter.

233

234 Antibody neutralization

235 HEK293T cells were transfected with human ACE2 and TMPRSS2 by TransIT-2020. After 24 236 hours cells were plated into black 96-well tissue culture treated plates. Serum or plasma was 237 diluted to 1:20 followed by four subsequent 1:4 dilutions. Per well, 50 µl of pseudovirus harboring either SARS-CoV-2 S, VSV-G or EboGP (adjusted to result in ~10,000 RLU in target 238 239 cells) was mixed with 50 µl of the respective serum or plasma dilution to give a final series of 240 longitudinal serum or plasma dilutions starting at 1:40 and incubated for one hour at 37°C. 241 Controls included wells with VSV ΔG (no envelope), without added serum/plasma, and with 242 serum predetermined to possess or lack neutralizing activity. Subsequently, the 100 μ l mix was 243 added to the target cells (performed in duplicate) and cells were incubated for 24 hours at 37°C. 244 Supernatants were then removed, cells were lysed, and luciferase activity was read as per 245 manufacturer instructions. Results were calculated as a percentage of no serum control. Each 246 plate was qualified by lack of infection with the no envelope control, and performance of

positive and negative controls. Non-linear regression curves and 80% neutralization titers(NT80) were calculated in GraphPad Prism.

249

250 Statistical analysis

251 We calculated positive percent agreement (PPA), negative percent agreement (NPA), and overall 252 percent agreement (OPA) between the neutralizing antibody result and IgG, assuming IgG to be 253 the gold standard. We then calculated PPA, NPA, and OPA between the neutralizing antibody 254 result and IgM, assuming IgM to be the gold standard. We calculated 95% exact binomial 255 (Clopper-Pearson) confidence intervals for each proportion. IgG, IgM and NT80 levels were 256 non-normally distributed and were summarized using medians and interquartile ranges. We 257 compared antibody levels to dichotomously-defined clinical characteristics at various time points 258 using Wilcoxon rank sum tests. The correlations between age and IgG, IgM, and NT levels were 259 calculated using Spearman non-parametric correlation coefficients. Statistical calculations were 260 performed using python libraries scipy.stats, sklearn.metrics.auc and statsmodels.stats as well as 261 Stata v15.1 (College Station, TX).

262

263

264

Percentage of positive specimens from patients with positive SARS-CoV2 RT-PCR grouped by days since symptom onset and immune status												
	All Patient Samples				Immunocompetent Only				Immunocompromised only			
Assay	Total N	positive	%	95% CI	Total N	positive	%	95% CI	Total N	positive	%	95% CI
Architect SARS-CoV-2 IgG												
Day 1-7	41	12	29.3	23.7 - 35.6	35	10	28.6	22.5 - 35.5	6	2	33.3	16.1 - 55.3
Day 8-14	106	68	64.2	60.5 - 67.7	82	53	64.6	60.4 - 68.7	24	15	62.5	53.5 - 70.7
Day 15-21	113	102	90.3	87.7 - 92.3	77	72	93.5	90.5 - 95.6	36	30	83.3	77.1 - 88.1
Day 22+	163	158	96.9	95.5 - 97.9	102	101	99	97.4 - 99.7	61	57	93.4	89.9 - 95.8
All	423	340	80.4	78.9 - 81.7	296	236	79. 7	77.9 - 81.4	127	104	81.9	79.0 - 84.4
Architect SARS-CoV-2 IgM												
Day 1-7	26	10	38.5	30.6 - 47.0	22	9	40.9	32.1 - 50.4	4	1	25.0	6.9 - 54.4
Day 8-14	91	68	74.7	70.9 - 78.1	70	54	77.1	72.8 - 80.9	21	14	66.7	56.9 - 75.2
Day 15-21	83	75	90.4	87.2 - 92.8	53	49	92.5	88.4 - 95.2	30	26	86.7	79.9 - 91.5
Day 22+	146	143	97.9	96.5 - 98.8	91	90	98.9	97.1 - 99.7	55	53	96.4	93.0 - 98.3
All	346	296	85.5	84.1 - 86.9	236	202	85.6	83.7 - 87.2	110	94	85.5	82.5 - 87.9
				1	Antibody N	eutralizatio	on Assay	y				
Day 1-7	10	4	40.0	26.1 - 55.5	9	3	33.3	19.6 - 50.2	1	1	100	25.0 - 100
Day 8-14	24	14	58.3	49.4 - 66.8	18	12	66.7	55.9 - 76.0	6	2	33.3	16.1 - 55.3
Day 15-21	10	7	70.0	54.2 - 82.4	6	5	83.3	61.1 - 95.3	4	2	50.0	24.3 - 75.7
Day 22+	14	13	92.9	81.9 - 98.0	9	9	100	85.7 - 100	5	4	80.0	54.6 - 94.4
All	58	38	65.5	60.3 - 70.4	42	29	69.0	62.8 - 74.7	16	9	56.2	44.8 - 67.1

266

267 Table 1: Clinical sensitivities of the Abbott Architect SARS-CoV-2 IgG and IgM and *in vitro* neutralization assays

Clinical sensitivity of each assay, defined as the percent of samples from RT-PCR confirmed SARS-CoV-2 infected patients that test positive in each assay. Total numbers of samples, positive samples, and percent positive among total samples with 95% confidence intervals (CI) are shown for the indicated time frames for samples from all patients (left column), samples from immunocompetent patients only (middle column), and samples from immunocompromised patients only (right column.) Immunocompromised patients: six solid organ transplant recipients on tacrolimus and MMF and one rheumatoid arthritis patient on methotrexate and infliximab.

273 FIGURE LEGENDS

274

275 Figure 1: Seroprevalence of Antibodies to SARS-CoV-2

276 (A) Schematic of testing performed and location of patient populations assessed. (B) IgG S/C 277 ratios for SARS-CoV-2 PCR-positive patient samples for the indicated weekly timeframes post-278 onset of symptoms (if multiple samples per patient were collected, the sample with the highest 279 S/C value within each time frame is plotted). The percent of patients with positive antibody 280 responses measured within each timeframe is indicated below the graphs. (C) IgG S/C ratios 281 measured in pre-COVID samples; specificity and number of samples is indicated on graph. (D) Receiver operating characteristic (ROC) curves for IgG levels for all samples from SARS-CoV-2 282 283 PCR-positive patients within the indicated weekly time frames. AUCs for are 0.537 (day 1-7), 284 0.827 (day 8-14), 0.946 (day 15-21), 0.990 (day 22+). (E) IgM S/C ratios, as in (B). (F) IgM S/C 285 ratios measured in pre-COVID samples. (G) ROC curves for IgM levels, as in (D); AUCs are 286 0.720 (day 0-7), 0.955 (day 8-14), 0.970 (day 15-21), 0.999 (day 22+). IgG (H) and IgM (I) S/C 287 ratios were determined for hospitalized patients and outpatients and blood donors on whom SARS-CoV-2 PCR testing was positive or negative or was not performed. Numbers of 288 289 seroreactive and total individuals tested are shown in tables below the graphs. The circled data 290 points in (H) were additionally tested by the VITROS and neutralization assays. For patients 291 with multiple samples, the single highest S/C value is plotted. In (B), (C), and (H), the dotted 292 line at 1.4 indicates cutoff for IgG positivity; in (E), (F), and (I), the dotted line at 0.6 indicates 293 cutoff for IgM positivity; data points in black and gray are above and below the indicated 294 cutoffs, respectively.

295

Figure 2: Longitudinal dynamics and *in vitro* neutralizing activity of antibodies against SARS-CoV-2

(A) IgG and IgM levels for SARS-CoV-2 PCR positive matched patient samples. Percent of data
points in each quadrant and positive percent agreement (PPA), negative percent agreement
(NPA), and overall percent agreement (OPA) between IgG and IgM are shown. 80%
neutralization titers (NT80) plotted against IgM (B) and IgG (C) S/C values. The cutoff for
NT80 was a titer level of >40; negative results are non-numeric (<40) and are plotted at 35 for
visualization purposes. (D-F), IgM (D) and IgG (E) S/C ratios and NT80 titers (F) for SARS-

304 CoV-2 PCR-positive patients were plotted against day post symptom onset. 305 Immunocompromised patients are shown in blue. In (**D**, **E**), for patients with multiple same-day 306 samples, the sample with the highest S/C value is plotted. (G) For the 6 SARS-CoV-2 PCR-307 positive patients whose IgM, IgG, and NT80 seroconversion events were captured during serial 308 sampling, the days post-symptom onset seroconversion events are compared. (H) NT80 activity 309 was evaluated per patient for the indicated time frames post onset of symptoms. The percent of 310 patients with detectable NT80 activity measured within each time frame is indicated below the 311 graphs. If multiple samples per patient were collected, the sample with the highest NT80 value 312 within each time frame was used. (I) The average NT80 activity (right axis) and IgG and IgM 313 (left axis) levels are plotted by day post-symptom onset (left); corresponding graphs for 314 individual patients are shown in a 3x3 grid (right). If multiple samples per patient were collected, 315 the sample with the highest S/C or NT80 value per time frame was used.

316

Table S1: Baseline demographic characteristics, presenting symptoms, chronic medical
 conditions, medications, and radiographic findings of 43 SARS-CoV-2 PCR-positive UCSF
 outpatients and hospitalized patients.

320

321 Table S2: Descriptive demographic characteristics of individuals who donated blood at San
 322 Francisco Bay Area community blood centers (Vitalant Research Institute).

- 323
- 324 **References**
- 325

Zhu, N. *et al.* A Novel Coronavirus from Patients with Pneumonia in China, 2019. *N. Engl. J. Med.* 382, 727–733 (2020).

328 2. Wu, Z. & McGoogan, J. M. Characteristics of and Important Lessons From the Coronavirus

- 329 Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From
- the Chinese Center for Disease Control and Prevention. J. Am. Med. Assoc. (2020)
- doi:10.1001/jama.2020.2648.

- 332 3. Yang, X. et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2
- 333 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. *Lancet*
- 334 *Respir. Med.* (2020) doi:10.1016/S2213-2600(20)30079-5.
- 335 4. Abbott Laboratories. SARS-CoV-2 IgG [package insert]. (2020).
- 336 5. Bryan, A. et al. Performance Characteristics of the Abbott Architect SARS-CoV-2 IgG
- 337 Assay and Seroprevalence in Boise, Idaho. J. Clin. Microbiol. (2020)
- doi:10.1128/JCM.00941-20.
- 6. Long, Q.-X. et al. Antibody responses to SARS-CoV-2 in patients with COVID-19. Nat.
- 340 *Med.* 1–4 (2020) doi:10.1038/s41591-020-0897-1.
- 341 7. Zhao, J. *et al.* Antibody responses to SARS-CoV-2 in patients of novel coronavirus disease
 342 2019. *Clin. Infect. Dis.* (2020) doi:10.1093/cid/ciaa344.
- 343 8. Corman, V. M. et al. Viral Shedding and Antibody Response in 37 Patients With Middle
- East Respiratory Syndrome Coronavirus Infection. *Clin. Infect. Dis.* **62**, 477–483 (2016).
- 345 9. Hsueh, P.-R., Huang, L.-M., Chen, P.-J., Kao, C.-L. & Yang, P.-C. Chronological evolution
- of IgM, IgA, IgG and neutralisation antibodies after infection with SARS-associated
- 347 coronavirus. *Clin. Microbiol. Infect.* **10**, 1062–1066 (2004).
- 10. Sun, B. et al. Kinetics of SARS-CoV-2 specific IgM and IgG responses in COVID-19
- 349 patients. *Emerg. Microbes Infect.* **0**, 1–36 (2020).
- 350 11. Whitman, J. D. *et al.* Test performance evaluation of SARS-CoV-2 serological assays.
- 351 Preprint at <u>https://www.medrxiv.org/content/10.1101/2020.04.25.20074856v1</u> (2020).
- 12. Bendavid, E. *et al.* COVID-19 antibody seroprevalence in Santa Clara County, California.
- 353 Preprint at https://www.medrxiv.org/content/10.1101/2020.04.14.200624363v2 (2020).

354	13. Sood, N, et al. Seroprevalence of SARS-CoV-2-specific antibodies among adults in Los
355	Angeles County, California, on April 10-11, 2020. JAMA, doi: 10.1001/jama.2020.8279
356	(2020).
357	14. Hogan, C. A., Sahoo, M. K. & Pinsky, B. A. Sample Pooling as a Strategy to Detect
358	Community Transmission of SARS-CoV-2. J. Am. Med. Assoc. (2020)
359	doi:10.1001/jama.2020.5445.
360	15. Ortho Clinical Diagnostics. VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total
361	test [package insert]. (2020)
362	16. Hoffmann, M. et al. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is
363	Blocked by a Clinically Proven Protease Inhibitor. Cell 181, 271-280.e8 (2020).
364	
365	Acknowledgments
366	We thank the patients and their families at UCSF without whom collecting and providing this
367	aggregate data would not have been possible.
368	
369	Competing Interests
370	CYC is the director of the UCSF-Abbott Viral Diagnostics and Discovery Center (VDDC) and
371	receives research support funding from Abbott Laboratories. JP, MD, KC, SP, and JRH, Jr. are
372	employees of Abbott Laboratories. The other authors have no competing interests to declare.
373	
374	Contributions
375	C.Y.C. conceived, designed, and supervised the study. D.L.N., and G.M.G. coordinated the
376	study. D.L.N., G.M.G., B.R.S., A.G.L., S.P.B., J.B., and C.Y.C. analyzed data, designed figures,
377	and wrote and edited the manuscript. A.S.G., V.S., C.S.S.M., A.G., D.R.G., E.H., W.G., Y.A.S.,
378	C.W., K.R., J.H., F.A., L.P., CY.O., C.M.L. contributed to the collection of clinical specimens.
379	K.S., T.K., and E.C.T. coordinated clinical sample collection and IgG testing. S.M. provided

380 clinical data and facilitated sample collection. L.M.H., K.T., N.A., D.N.N., N.M.N., and D.Q.

performed chart review. M.S., B.C., V.G., P.W., M.B., and J.D.W. coordinated blood donor
samples and data. S.Z., L.D., G.S., and S.K.P. performed neutralizing antibody assays. J.M.C.H.,
J.P., M.R., K.C., and S.P. performed IgG and IgM testing and provided data establishing testing
characteristics of SARS-CoV-2 IgG and IgM assays. N.K.H. performed biostatistical analysis
and review. All authors read the manuscript and agreed to its contents.

386

387 Funding

- 388 This work was funded by NIH grants R01-HL105704 (CYC) from the National Heart, Lung, and
- 389 Blood Institute, R33-129077 (CYC) the National Institute of Allergy and Infectious Diseases, the
- 390 Charles and Helen Schwab Foundation (CYC). These funders had no role in study design, data
- 391 collection and analysis, writing the manuscript, or decision to publish. This work was also
- 392 funded in part by Abbott Laboratories. Employees of Abbott laboratories (J.P., M.R., K.C., S.P.,
- 393 J.H.) contributed to sample collection, IgG and IgM testing, and data analysis but had no role in
- the study design, writing the manuscript, or decision to publish.
- 395

396 Data Availability

Raw data used in this study, including de-identified patient metadata and test results, areavailable upon request.

399



